A share price of Supernus Pharmaceuticals Inc [SUPN] is currently trading at $41.23, down -0.55%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SUPN shares have gain 16.12% over the last week, with a monthly amount glided 24.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on July 30, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $42 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 19, 2025, and dropped its price target to $36. On January 06, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $57 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $36 on September 11, 2024. In a note dated April 13, 2021, Jefferies upgraded an Buy rating on this stock and boosted its target price from $25 to $40.
Supernus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $29.16 and $43.62. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $41.23 at the most recent close of the market. An investor can expect a potential return of 1.87% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Trailing Twelve Months sales for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] were 665.12M which represents -1.71% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] is 2.58. In addition, the Quick Ratio stands at 2.43 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 3.48, the price to book ratio is 2.17 and price to earnings (TTM) ratio is 36.03.
Transactions by insiders
Recent insider trading involved Khattar Jack A., President, CEO, that happened on Aug 06 ’25 when 0.14 million shares were sold. Director, JACK A KHATTAR completed a deal on Aug 06 ’25 to buy 0.14 million shares. Meanwhile, SVP, Chief Medical Officer Rubin Jonathan sold 927.0 shares on Feb 21 ’25.
